低位直肠癌术后化学治疗辅助使用参术益中汤近远期疗效研究

目的探讨低位直肠癌术后化学治疗(简称化疗)辅助使用参术益中汤的近远期疗效。方法选取医院2013年1月至2014年12月收治并行直肠癌根治术的低位直肠癌患者82例,按随机数字表法分为观察组和对照组,各41例。两组患者术后均予FOLFOX化疗方案,观察组患者加用参术益中汤辅助治疗。结果治疗后,两组患者的CD3^+,CD4^+水平和CD4^+/CD8均明显升高,CD8^+明显降低,且观察组明显优于对照组(P<0.05);治疗后,两组患者的生活质量(包括生理功能、心理功能、日常活动、社交功能)评分均明显升高,且观察组明显高于对照组(P<0.05);观察组不良反应发生率与对照组相当(34.15%比24.39%,P>0.05);门诊随访5年,观察组患者的肿瘤复发率、远端转移率均明显低于对照组,而5年生存率明显高于对照组(P<0.05)。结论低位直肠癌术后化疗辅助使用参术益中汤,可提高免疫功能和生活质量,且远期疗效更好。

Short-term and Long-term Efficacy and Safety of Shenzhu Yizhong Decoction in Adjuvant Treatment of Postoperative Chemotherapy for Low Rectal Cancer

Objective To study the short-term and long-term efficacy and safety of Shenzhu Yizhong Decoction in adjuvant treatment of low rectal cancer after chemotherapy.Methods A total of 82 patients with low rectal cancer who were treated in the hospital from January 2013 to December 2014 were selected and divided into the observation group and the control group according to random number table method,41 cases in each group.Both groups received FOLFOX chemotherapy after operation,and the observation group was added with Shenzhu Yizhong Decoction as an adjuvant therapy.Results After treatment,the levels of CD3^^+,CD4^+,CD4^+/CD8^+in the two groups were significantly increased,while the level of CD8^+were decreased,and the improvements in the observation groups were better than those in the control group(P<0.05);the scores of quality of life including physiological function,psychological function,daily activity and social function in the observation group were higher than those in the control group(P<0.05);the incidence of adverse reactions in the observation group had no significant difference with the control group(34.15%vs.24.39%,P>0.05);in the 5-year follow-up,the recurrence rate and distal metastasis rate of the observation group were lower than those in the control group,while the 5-year survival rate was higher than that in the control group(P<0.05).Conclusion The adjuvant treatment of Shenzhu Yizhong Decoction can improve the immune function and quality of life of patients with low rectal cancer after chemotherapy,and the long-term clinical efficacy is better.